PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.
PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
|Alternate Symbols: ||MGC72007; RPS17L1; RPS17L2; S17|
|PharmGKB Accession Id:||PA34797|
|Cytogenetic Location:||chr15 : q25.2 - q25.2|
|GP mRNA Boundary†:||chr15 : 82821161 - 82824865|
|GP Gene Boundary†:||chr15 : 82818161 - 82834865|
PharmGKB Curated Pathways
Pathways created internally by PharmGKB based primarily on literature evidence.
PharmGKB contains no curated pathways for this gene. If you would like to volunteer to work on a pathway, please let us know.
Links to non-PharmGKB pathways.
- Eukaryotic Translation Termination - (Reactome via Pathway Interaction Database)
- Formation of a pool of free 40S subunits - (Reactome via Pathway Interaction Database)
- Formation of the ternary complex, and subsequently, the 43S complex - (Reactome via Pathway Interaction Database)
- GTP hydrolysis and joining of the 60S ribosomal subunit - (Reactome via Pathway Interaction Database)
- L13a-mediated translational silencing of Ceruloplasmin expression - (Reactome via Pathway Interaction Database)
- Peptide chain elongation - (Reactome via Pathway Interaction Database)
- Ribosomal scanning and start codon recognition - (Reactome via Pathway Interaction Database)
- Translation initiation complex formation - (Reactome via Pathway Interaction Database)
- Viral mRNA Translation - (Reactome via Pathway Interaction Database)
Publications related to RPS17: 2
The following icons indicate that data of a certain type is available:
- DG Dosing Guideline information is available
- DL Drug Label information is available
- CA High-level Clinical Annotation is available
- VA Variant Annotation is available
- VIP VIP information is available
- PW Pathway is available
[ close ]
||Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. American journal of human genetics. 2008. Gazda Hanna T, et al.|
||Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Human mutation. 2007. Cmejla Radek, et al.|